Resomelagon: Resomelagon 100mg, orally, once daily.
Placebo: Placebo
Standard Treatment: Hydration and symptomatic therapy as indicated for Dengue fever.
Study summary
The goal of this clinical trial is to understand if Resomelagon can treat adult patients with Dengue virus infection. The main questions the investigators aim to answer are:
Is Resomelagon safe to use in patients with Dengue? Is Resomelagon able to reduce the duration of illness? (defined by clinical and laboratory criteria) Participants will be allocated to Resomelagon or placebo groups in this study and asked to take the medication and submitted to blood tests.
Eligibility
Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria:
* Patients who are 18 to 65 years old;
* Able to understand study procedures and give informed consent;
* Presents with more than 36 and less than 84h since symptoms onset;
* Symptoms compatible with dengue infection (fever, myalgia, arthralgia, headache or conjunctivitis) with positive antigen test or polymerase chain reaction test.
Exclusion Criteria:
* Has any comorbidity which is perceived as significant by the investigator;
* Significant laboratory abnormalities discovered at triage: Hemoglobin \<10g/dL; Platelet count \< 50.000/microL; alanine transaminase \> 3x upper limit of normal; Total bilirubin \>1,5 x upper limit of normal; glomerular filtration rate \< 60mls/min/1,73m2;
* Contraindications or known hypersensitivity to Resomelagon;
* Presents as dengue with warning signs or severe dengue at inclusion;
* Currently participating in another drug clinical trial;
* Clinical evidence of another infection that might explain current symptoms;
* Pregnant women or women actively trying to achieve pregnancy.
Primary outcome measure(s)
Evaluate safety of Resomelagon in Dengue patients — 28 days Incidence of clinical or laboratory adverse events. All symptoms, illness and laboratory abnormalities will be graded by the investigators in accordance to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Adverse events graded 3 or more in severity will be registered. Serious adverse events will be reported and registered. Incidence of adverse events will be compared between placebo and intervention groups.
Efficacy of Resomelagon in decreasing illness duration — 10 days Time to resolution of illness as defined by a composite outcome:
Patient afebrile for 48 hours without paracetamol (or other drugs to treat fever) ingestion; Rising platelet counts of \>20% of the lowest, or normal platelet counts if the patient did not have thrombocytopenia, following two consecutive measurements from the lowest platelet count Haematocrit stabilized or return to the normal hematocrit for age \& sex, following two consecutive measurements Absence of bleeding or significant vomiting for 48h.
Trial sites (2)
Facility
City
Region
Status
Clinical Research Unit
Belo Horizonte
Minas Gerais
Recruiting
Centro Integrado de Pesquisa
São José do Rio Preto
São Paulo
Not Yet Recruiting
More Federal University of Minas Gerais trials in Brazil
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
